雅虎香港 搜尋

搜尋結果

1. www.webnewswire.com › 2024/03/30 › japan-eisai-to-divestJapan – Eisai to Divest Rights for Merislon and Myonal ...

   www.webnewswire.com › 2024/03/30 › japan-eisai-to-divest

   • 網頁紀錄

   2024年3月30日 · Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan

2. www.nasdaq.com › press-release › eisai-to-divest-rights-forEisai to Divest Rights for Merislon and Myonal in Japan to K ...

   www.nasdaq.com › press-release › eisai-to-divest-rights-for

   2024年3月29日 · TOKYO, Mar 29, 2024--- Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon and ...

3. www.drugs.com › international › merislonMerislon (International database) - Drugs.com

   www.drugs.com › international › merislon

   • 網頁紀錄

   Merislon (International) Merislon may be available in the countries listed below. Ingredient matches for Merislon ... Japan Malaysia Myanmar Singapore Taiwan Thailand Vietnam Important Notice: The Drugs.com international database is in BETA release. This It ...

4. www.asiaone.com › business › eisai-divest-rights-merislon-andEisai to Divest Rights for Merislon and Myonal in Japan to K ...

   www.asiaone.com › business › eisai-divest-rights-merislon-and

   • 網頁紀錄

   2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon ...

5. www.drugoffice.gov.hk › eps › drugDrug Office | 藥 物 辦 公 室

   www.drugoffice.gov.hk › eps › drug

   • 網頁紀錄

   MERISLON TAB 6MG Registration No.: HK-48603 Certificate Holder: EISAI (HONG KONG) CO LTD Certificate Holder Address: FLAT/RM D, 18/F, LEE & MAN 169 ELECTRIC ROAD, NORTH POINT, HONG KONG : Part 1 ...

6. www.pharmaceutical-technology.com › news › eisai-divest-rightsEisai to divest rights for two therapies to Kaken - ...

   www.pharmaceutical-technology.com › news › eisai-divest-rights

   • 網頁紀錄

   2024年4月2日 · Eisai has signed an agreement for the divestiture of rights for Merislon and Myonal, two of its long-standing products in Japan, to Kaken Pharmaceutical. The transaction is valued at Y3.8bn ($25.10m).

7. www.otandp.com › zh-hk › medicines-in-hong-kong敏使朗（Merislon）

   www.otandp.com › zh-hk › medicines-in-hong-kong

   • 網頁紀錄

   敏使朗（Merislon） 敏使朗是一種常見的頭暈藥，主要用於治療眩暈和平衡障礙的藥物。 簡介 敏使朗 （Merislon） 是什麼？ 敏使朗是一種常見的頭暈藥，主要用於治療眩暈和平衡障礙的藥物。 配方及成分組合 敏使朗的活性成分為倍他司汀（Betahistine ），這種成分被認為能改善內耳的血流，並可能會 ...